Exercise-based Frailty Intervention in Lung Transplantation (XFIT)
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Apr 28, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The XFIT study is looking at a new program that combines exercise and behavioral training delivered through telehealth to help lung transplant candidates who are frail. The main goals of this study are to see if the program is safe, if people find it easy to participate in, and if it actually helps improve their strength and overall physical ability. Participants will either take part in the 8-week XFIT program or receive standard care.
To join the study, participants need to be between 18 and 75 years old, speak either English or Spanish, and be on a certain level of oxygen support during a walking test. They should also have a specific score on a physical performance test. However, people who live alone, have a very low body weight, or are already in a rehabilitation program may not be eligible. This study is not yet recruiting participants, but it aims to provide important insights into how exercise can benefit those preparing for a lung transplant.
Gender
ALL
Eligibility criteria
- • Group 1
- Inclusion Criteria:
- • Age 18 - 65 years
- • Lung Transplant Candidates
- • Speaks English or Spanish
- • ≤ 8LPM O2 on 6MWT
- • SPPB score ≤ 10
- Exclusion Criteria:
- • Lives Alone
- • BMI \< 18.0 kg/m2
- • Engaged in clinical pulmonary rehabilitation program
- • Severe pHTN (RHC mPAP ≥ 30 mmHg or TTE PASP ≥ 60mmHg or moderately/severely reduced RV systolic function on TTE
- • Deemed unsafe by site PI
- • Group 2
- Inclusion Criteria:
- • Age 18 - 75 years
- • Speaks English or Spanish
- • ≤ 15LPM O2 on 6MWT
- • SPPB score ≤ 10
- Exclusion Criteria:
- • Lives Alone
- • BMI \< 18.0 kg/m2
- • Engaged in clinical pulmonary rehabilitation program
- • Severely reduced RV systolic function on TTE
- • Deemed unsafe by site PI
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
San Francisco, California, United States
Patients applied
Trial Officials
Jonathan Singer, MD, MS
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported